FDA Drug Facility Inspection Backlog: What It Means for Your Audit

Why the Backlog Matters More Than the Headlines Suggest

Most coverage of the FDA drug facility inspection backlog treats it as a story about the agency falling behind. That's true, but it misses the part that should actually change how you prepare. A backlog doesn't mean less scrutiny is coming to your facility. It means the scrutiny is being redistributed, and that redistribution follows a logic. If you understand the logic, you can make a reasonable guess about where your facility sits in line, and what the inspection looks like when it finally arrives.

I've spent years working as a GMP certification consultant, walking drug and dietary supplement manufacturers through CGMP readiness under 21 CFR Part 211, and the question I get most often right now isn't "will we get inspected." It's "when, by whom, and will it be worse because they're behind schedule." Those are fair questions. Here's what the record actually shows about the FDA drug facility inspection backlog, and what a facility preparing for GMP certification should do about it.

What Happened to FDA's Inspection Program

FDA postponed most facility inspections starting in March 2020, and the effects are still working through the system. As the agency worked through its inspection backlog, its surveillance inspection mix shifted hard toward overdue facilities — establishments that had never been inspected, or hadn't been inspected in more than five years, moved to the front of the queue instead of the back. That group came to account for a growing share of surveillance inspections in the years following the shutdown, eventually making up the majority of them as the backlog persisted.

That statistic is the whole story in miniature. FDA isn't just behind. It has had to triage, and triage means the facilities that went the longest without a look are the ones getting prioritized now, not deprioritized. The same GAO report puts the number of drug manufacturing sites not inspected in over five years at roughly 2,000, spanning both foreign and domestic establishments still producing drugs Americans take every day.

Inspection volume tells a related but separate story. Here's how the totals compare:

Notice the asymmetry. Domestic inspection counts in FY2023 actually exceeded the FY2019 baseline, but foreign inspections remained well below it. If your facility is outside the United States, that gap is the single most important number in this article. The queue you're in is longer and moving slower than the domestic queue, even as the backlog logic pushes overdue sites toward the front of both lines.

Part of the slowdown is a workforce problem, not just a scheduling one. As of mid-2024, FDA had only about 20 employees dedicated to foreign inspection assignment work, per GAO-24-107359, after losing a number of experienced investigators and backfilling with less experienced staff who take years to reach full proficiency. A newer investigator working from a checklist tends to document more literally and escalate more readily than someone who has seen the same deviation a hundred times and knows which ones matter. That has real consequences for how a Form 483 gets written, and it's one more reason a facility-level GMP audit before the real one is worth the cost.

How FDA Decides Who Gets Inspected Next

This isn't random, and it isn't first-come-first-served. FDA's Center for Drug Evaluation and Research runs a Site Selection Model, documented in an internal Manual of Policies and Procedures, that ranks manufacturing sites for routine CGMP surveillance inspection based on risk. The ranking pulls in compliance history, recall history and severity, the inherent risk of the drug product being manufactured, and how long it's been since the site was last inspected.

This risk-based approach isn't new, and it isn't a pandemic improvisation. The Food and Drug Administration Safety and Innovation Act of 2012 amended Section 510(h) of the Food, Drug, and Cosmetic Act. The amendment eliminated the old fixed two-year inspection cycle for domestic drug establishments and replaced it with a risk-based schedule, one that applies the same way to domestic and foreign facilities. The FDA drug facility inspection backlog didn't create risk-based prioritization. It just made the prioritization matter more, because more overdue facilities are now competing for a limited number of inspection slots.

The model itself keeps evolving. FDA updated the Site Selection Model MAPP in July 2023 to add a new risk factor: the compliance history of the country or region where an establishment is located, a change required by an amendment to Section 510(h)(4) made under the Food and Drug Omnibus Reform Act of 2022. In plain terms, your facility's position in the queue is now partly a function of what other facilities in your country have done. A single country's compliance record can push every other facility in that country up or down the list.

What This Actually Means for Your Next Audit

You may go longer between inspections, but the interval isn't the risk

The risk is what happens the day someone shows up. A facility that hasn't seen an investigator in six or seven years has accumulated more time for undocumented drift: process changes that never got a formal change control, SOPs that fell out of sync with actual practice, training records with gaps nobody caught because nobody was checking. An investigator working from a backlog list already has a reason to look harder, precisely because the interval itself is now a documented risk factor in the Site Selection Model. This is exactly the kind of gap a GMP certification review is built to catch before FDA does.

Novice investigators tend to write more, not less

If your inspection is staffed by someone newer to the role, expect more items documented on the Form 483, even for observations an experienced investigator might have handled as a verbal note. That's not a criticism of the investigator. It's a predictable consequence of a workforce still rebuilding institutional judgment, and it means your response process matters more than it used to, not less.

Foreign facilities should assume a longer wait, then a harder look

With foreign inspection capacity still constrained, the gap between "due for inspection" and "actually inspected" runs longer overseas. When the inspection arrives, it may also carry the added weight of your country's aggregate compliance history under the newer Site Selection Model risk factor. That's a reason to keep your own house especially clean if you operate in a region where recent enforcement activity has been rocky, and a reason to bring in outside GMP compliance consulting well before the visit rather than after a warning letter.

For-cause and unannounced inspections aren't going away

Everything above concerns routine surveillance inspections. FDA's authority to inspect for-cause, in response to a complaint, an adverse event signal, or a suspicious pattern, doesn't run on the same queue and isn't affected by the surveillance backlog in the same way. Don't read "the backlog favors overdue facilities" as "we're safe because we were inspected recently." A recent clean inspection doesn't take you off the list for a for-cause visit.

The table below summarizes how the two inspection tracks differ:

Preparing for an Inspection You Can't Fully Predict

The honest answer to "when will we be inspected" is that nobody outside FDA knows for certain, and the agency doesn't publish individual facility schedules. What you can control is your state of readiness on any given day, which is the only variable that actually matters once the investigator is standing in your lobby. This is the same discipline a GMP certification consultant brings to a client engagement: build the system so that any given day looks like the day before an inspection, because for a growing share of facilities, it now is.

A few things worth doing now, regardless of where you think you sit in the queue:

• Run your own gap assessment against 21 CFR Part 211 before FDA does it for you. Focus on the sections that generate the most 483 observations in practice: production record review (211.192), laboratory controls (211.160 through 211.176), and equipment cleaning and maintenance documentation (211.67).
• Reconcile your SOPs against actual floor practice. A long gap since your last inspection is exactly the kind of interval where documented procedure and daily practice quietly drift apart.
• Rehearse your 483 response process, not just your CAPA content. Practice the internal handoffs: who drafts, who reviews, who signs, and whether you can hit the 15-business-day response window described in FDA's Regulatory Procedures Manual under real conditions, not ideal ones.
• Check your recall and complaint history for anything that would raise your Site Selection Model risk score. If you've had a recent recall, assume it's a factor in your prioritization, not a closed chapter.
• If you manufacture outside the U.S., track your country's recent FDA enforcement pattern. It's now a documented input into when your own site gets flagged, under the July 2023 MAPP update.
• Get an outside GMP audit on the calendar. A quality management system that only gets tested by FDA is a quality management system that's untested until it matters most.

None of this requires guessing FDA's internal calendar. It requires treating every day as the day before an inspection, because for a growing number of facilities caught in the FDA drug facility inspection backlog, that's closer to true than it's been in years.

If your quality system needs an outside read before FDA provides one, GMP certification support is a reasonable place to start, and a structured GMP certification process will surface most of the gaps an investigator would find first.

Frequently Asked Questions

Does the inspection backlog mean my facility is less likely to be inspected this year? Not necessarily. As explained above, FDA has been prioritizing exactly that kind of facility. If yours hasn't been inspected in more than five years, the backlog makes an inspection more likely this year, not less.

Is FDA still required to inspect drug facilities every two years? No. That fixed cycle was replaced in 2012 by the risk-based schedule established under the Food and Drug Administration Safety and Innovation Act, and it still governs inspections today.

How does FDA decide which facility gets inspected first? FDA's Center for Drug Evaluation and Research uses a Site Selection Model that scores manufacturing sites on compliance history, recall history, the inherent risk of the product, time since last inspection, and, since a July 2023 update, the compliance history of the country or region where the site is located.

Does a longer gap since my last inspection increase my risk score? Time since last inspection is one of the documented risk factors in FDA's Site Selection Model, so a longer interval is a contributing factor, though not the only one.

Are for-cause inspections affected by the backlog the same way as routine surveillance inspections? No. For-cause inspections, triggered by complaints, adverse events, or specific concerns, operate outside the routine surveillance queue and aren't governed by the same backlog dynamics described in GAO's reporting on FDA's inspection program.

Last updated: 2026-09-04